ACTILITY
Actility, the industry leader in low power wide area networking, is proud to celebrate the successful deployment of the world’s first nationwide LoRa network for the Internet of Things with Dutch telecom operator KPN. After an intense period of 8 months’ work, several hundred LoRa antennas have been installed all over the Netherlands. KPN’s LoRa project initially went live in the cities of Rotterdam and The Hague. Thanks to strong positive feedback and consumer interest in the early deployments, the network roll-out was accelerated at the beginning of this year, and has just been completed. The KPN network will support uses as varied as street lighting, street signage, waste management and animal tracking.
Actility and KPN have been pioneering the world-leading development of the European Internet of Things together since 2014. Combining Actility’s innovative ThingPark solution for the Internet of Things with KPN’s leading mobile network gives the country a world #1 “best-in-class” solution. It will address the needs of a wide variety of markets with very different requirements, but sharing the common need to connect sensors cost-effectively, over long distances and in both built-up areas and wide open countryside. KPN will leverage the ThingPark Wireless solution to connect a wide range of objects in markets as diverse as agriculture, smart building, transport infrastructure and healthcare applications.
One of the most attractive applications of KPN’s LoRa network is Smart Public Space Management. Citizens across the Netherlands will see a variety of benefits including improved street signage, better waste management in public spaces and smart street lighting.
“We congratulate KPN on being first in the world, thanks to their extremely efficient and successful roll-out across the Netherlands. KPN is a true pioneer and has made good on its ambition to turn the whole country into a smart nation, connecting cities and rural areas, and making life a little smarter for all its inhabitants”, says Actility’s CEO Mike Mulica.
“KPN is pleased with the fruitful collaboration with Actility, which allowed the successful nationwide roll-out in less than a year”, says Jacob Groote, Executive Vice President Service Platforms at KPN.
About Actility
Actility is an innovator and industry leader in LPWA (Low Power Wide Area) large scale infrastructure. Actility’s ThingPark™ is a next generation standards-based IoT platform. The ThingPark Wireless LPWA network provides long-range coverage for low-power consumption sensors. ThingPark Mash-up offers big data storage for sensor data and exposes sensor capabilities through an open API, enabling developers to create vertical applications using the installed base of sensors. The ThingPark platform offers embedded software solutions and cloud solutions to connect devices with innovative applications. With its dedicated online marketplace for IoT sensors, applications and network solutions, ThingPark simplifies and accelerates the roll-out of innovative IoT services. Actility is a founding member of the LoRa Alliance: the largest, most powerful open standards-based enabler of the Internet of Things. To find out more, visit www.thingpark.com .
About KPN: to learn more visit www.kpn.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160712006387/en/
Contact:
Actility
Anne van Gemert
anne.vangemert@actility.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom